Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
Stay up to date with the exciting new developments as we continue to grow.
Shield Therapeutics plc, announces positive results from the AEGIS-H2H clinical trial which compared Feraccru® (ferric maltol), a novel oral iron replacement therapy, to Ferinject® (ferric…
Shield Therapeutics plc, announces positive results from the open-label extension phase of the AEGIS-CKD pivotal study of Feraccru®, a novel oral ferric iron therapy that…
Shield Therapeutics plc, today provides a business and unaudited trading update for the year ended 31 December 2018. For further details and to view the…
Shield Therapeutics plc, announces it will be presenting at two investor presentations this month. For further details please click here or visit our events page. …
Shield Therapeutics plc, is pleased to announce the appointment of James Karis as non-executive Chairman of the Company with immediate effect. For further details click here.
Shield Therapeutics plc announces that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application…
Shield Therapeutics plc is pleased to note the announcement today by Norgine that they have launched Feraccru® in the UK. Feraccru® is a novel, effective…
Shield Therapeutics plc today announces that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Feraccru®, Shield’s…
Shield Therapeutics plc, today announces that it has received confirmation from the US FDA of its successful submission of an NDA for Feraccru®. For more…
